BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

26 related articles for article (PubMed ID: 35871690)

  • 1. Synthesis, Characterization, and Anticancer Activity of New N,N'-Diarylthiourea Derivative against Breast Cancer Cells.
    El-Atawy MA; Alsubaie MS; Alazmi ML; Hamed EA; Hanna DH; Ahmed HA; Omar AZ
    Molecules; 2023 Sep; 28(17):. PubMed ID: 37687250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of GAB1 in Cancer.
    Pérez-Baena MJ; Cordero-Pérez FJ; Pérez-Losada J; Holgado-Madruga M
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.
    Finn RS; Press MF; Dering J; Arbushites M; Koehler M; Oliva C; Williams LS; Di Leo A
    J Clin Oncol; 2009 Aug; 27(24):3908-15. PubMed ID: 19620495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.
    Chapman JA; Sgroi DC; Goss PE; Zarella E; Binns S; Zhang Y; Schnabel CA; Erlander MG; Pritchard KI; Han L; Badovinac-Crnjevic T; Shepherd LE; Pollak MN
    Breast Cancer Res Treat; 2016 May; 157(1):101-8. PubMed ID: 27116182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
    Massarweh S; Osborne CK; Creighton CJ; Qin L; Tsimelzon A; Huang S; Weiss H; Rimawi M; Schiff R
    Cancer Res; 2008 Feb; 68(3):826-33. PubMed ID: 18245484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of MNK1b DNA Aptamers That Inhibit Proliferation in MDA-MB231 Breast Cancer Cells.
    García-Recio EM; Pinto-Díez C; Pérez-Morgado MI; García-Hernández M; Fernández G; Martín ME; González VM
    Mol Ther Nucleic Acids; 2016 Jan; 5(1):e275. PubMed ID: 26730812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathways to tamoxifen resistance.
    Riggins RB; Schrecengost RS; Guerrero MS; Bouton AH
    Cancer Lett; 2007 Oct; 256(1):1-24. PubMed ID: 17475399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Her2/EGFR-PDGFR pathway aberrations associated with tamoxifen response in metastatic breast cancer patients.
    Malash I; Mansour O; Gaafar R; Shaarawy S; Abdellateif MS; Ahmed OS; Zekri AN; Bahnassy A
    J Egypt Natl Canc Inst; 2022 Jul; 34(1):31. PubMed ID: 35871690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
    Gee JM; Robertson JF; Gutteridge E; Ellis IO; Pinder SE; Rubini M; Nicholson RI
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S99-S111. PubMed ID: 16113104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.